Ftse Mib
33.541,98
-0,49%
DAX
18.155,24
-0,04%
S&P 500
5.477,90
0,16%
NASDAQ
17.805,16
0,49%
Bitcoin
60.968,84
0,26%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Salarius Pharmaceuticals Inc (SLRX) Salarius Pharmaceuticals Inc (SLRX) Notizie

Salarius Pharmaceuticals Inc

SLRX
2,44
-0,0101 (-0,41%)
27 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/6/202414:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/6/202414:05EDGAR2Form 8-K - Current report
17/6/202414:00GLOBEClinical Data on Salarius Pharmaceuticals’ Seclidemstat in..
14/6/202422:04EDGAR2Form 8-K - Current report
12/6/202414:00GLOBESalarius Pharmaceuticals Announces 1-for-8 Reverse Stock..
13/5/202422:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
22/3/202421:05GLOBESalarius Pharmaceuticals Reports Fourth Quarter and Full..
06/3/202422:02EDGAR2Form 8-K - Current report
22/2/202422:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202414:00GLOBESalarius Provides Update on Strategic Review Process and..
16/1/202414:00GLOBESalarius Pharmaceuticals Issued U.S. Patent for..
03/1/202414:30GLOBEInvestigator-initiated Phase 1/2 Clinical Trial Using..
09/11/202323:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202314:30GLOBESalarius Completes FDA Type B Meeting for Seclidemstat Ewing..
27/10/202321:57EDGAR2Form SC 13D - General statement of acquisition of beneficial..
06/9/202323:09EDGAR2Form 8-K - Current report
10/8/202322:14EDGAR2Form 8-K - Current report
10/8/202322:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:05GLOBESalarius Pharmaceuticals Reports Second Quarter 2023..
08/8/202322:05GLOBESalarius Pharmaceuticals Announces Plans to Explore..
12/7/202315:22EDGAR2Form 8-K - Current report
11/7/202314:30GLOBESalarius Pharmaceuticals Receives FDA Clearance of SP-3164..
Apertura: 2,60 Min: 2,41 Max: 2,65
Chiusura: 2,4501

La tua Cronologia

NASDAQ
SLRX
Salarius Pharmaceuticals
BTRX
USDDUSDT
Decentralized USD
ASX
CGI
Consolidated Global Investments
USOTC
CTPCF
Citic (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network